Malignant upper urinary tract obstruction in cancer patients: A systematic review
Abstract Objective To systematically summarise the current clinical evidence for de novo malignant upper urinary tract obstruction treatment with a focus on standards of reporting, patient outcomes and future research needs. Methods This review protocol was published via PROSPERO (CRD42022341588). O...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-05-01
|
| Series: | BJUI Compass |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/bco2.340 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846111282847023104 |
|---|---|
| author | Max Shah Francesca Blest James Blackmur Alexander Laird Shoba Dawson Jonathan Aning |
| author_facet | Max Shah Francesca Blest James Blackmur Alexander Laird Shoba Dawson Jonathan Aning |
| author_sort | Max Shah |
| collection | DOAJ |
| description | Abstract Objective To systematically summarise the current clinical evidence for de novo malignant upper urinary tract obstruction treatment with a focus on standards of reporting, patient outcomes and future research needs. Methods This review protocol was published via PROSPERO (CRD42022341588). OVID MEDLINE (R), EMBASE, Cochrane Central Register of Controlled Trials—CENTRAL were searched up to June 2022 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‐analyses. Prospective and retrospective studies were included. Results Of 941 articles identified, 82 with 8796 patients were eligible for inclusion. Most studies in the published literature are retrospective and investigate heterogenous malignancies. Percutaneous nephrostomy and ureteric stenting are the most studied interventions. Few studies describe the outcomes from no intervention or investigate patient perspectives. Overall reported median survival after intervention was around 11.7 months. A lack of standardised reporting of outcomes was evident. Conclusions Malignant upper urinary tract obstruction is an important clinical condition affecting patients globally. Overall survival after intervention appears poor however the current evidence base has significant limitations due to studies of low methodological quality and the lack of a standardised framework for reporting outcomes. We have provided a pragmatic framework for future studies based on the review to ensure a uniform methodology is utilised moving forward. |
| format | Article |
| id | doaj-art-c83f9c20c50540059a22da7d21ec376f |
| institution | Kabale University |
| issn | 2688-4526 |
| language | English |
| publishDate | 2024-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | BJUI Compass |
| spelling | doaj-art-c83f9c20c50540059a22da7d21ec376f2024-12-23T09:01:14ZengWileyBJUI Compass2688-45262024-05-015551953010.1002/bco2.340Malignant upper urinary tract obstruction in cancer patients: A systematic reviewMax Shah0Francesca Blest1James Blackmur2Alexander Laird3Shoba Dawson4Jonathan Aning5University of Bristol Bristol UKUniversity of Bristol Bristol UKDepartment of Urology Cambridge University Hospitals NHS Foundation Trust Cambridge UKDepartment of Urology, Western General Hospital Edinburgh UKUniversity of Bristol Bristol UKBristol Urological Institute, Southmead Hospital North Bristol Trust Bristol UKAbstract Objective To systematically summarise the current clinical evidence for de novo malignant upper urinary tract obstruction treatment with a focus on standards of reporting, patient outcomes and future research needs. Methods This review protocol was published via PROSPERO (CRD42022341588). OVID MEDLINE (R), EMBASE, Cochrane Central Register of Controlled Trials—CENTRAL were searched up to June 2022 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‐analyses. Prospective and retrospective studies were included. Results Of 941 articles identified, 82 with 8796 patients were eligible for inclusion. Most studies in the published literature are retrospective and investigate heterogenous malignancies. Percutaneous nephrostomy and ureteric stenting are the most studied interventions. Few studies describe the outcomes from no intervention or investigate patient perspectives. Overall reported median survival after intervention was around 11.7 months. A lack of standardised reporting of outcomes was evident. Conclusions Malignant upper urinary tract obstruction is an important clinical condition affecting patients globally. Overall survival after intervention appears poor however the current evidence base has significant limitations due to studies of low methodological quality and the lack of a standardised framework for reporting outcomes. We have provided a pragmatic framework for future studies based on the review to ensure a uniform methodology is utilised moving forward.https://doi.org/10.1002/bco2.340malignant ureteral obstructionnephrostomyreporting frameworkureteric stenturinary diversion |
| spellingShingle | Max Shah Francesca Blest James Blackmur Alexander Laird Shoba Dawson Jonathan Aning Malignant upper urinary tract obstruction in cancer patients: A systematic review BJUI Compass malignant ureteral obstruction nephrostomy reporting framework ureteric stent urinary diversion |
| title | Malignant upper urinary tract obstruction in cancer patients: A systematic review |
| title_full | Malignant upper urinary tract obstruction in cancer patients: A systematic review |
| title_fullStr | Malignant upper urinary tract obstruction in cancer patients: A systematic review |
| title_full_unstemmed | Malignant upper urinary tract obstruction in cancer patients: A systematic review |
| title_short | Malignant upper urinary tract obstruction in cancer patients: A systematic review |
| title_sort | malignant upper urinary tract obstruction in cancer patients a systematic review |
| topic | malignant ureteral obstruction nephrostomy reporting framework ureteric stent urinary diversion |
| url | https://doi.org/10.1002/bco2.340 |
| work_keys_str_mv | AT maxshah malignantupperurinarytractobstructionincancerpatientsasystematicreview AT francescablest malignantupperurinarytractobstructionincancerpatientsasystematicreview AT jamesblackmur malignantupperurinarytractobstructionincancerpatientsasystematicreview AT alexanderlaird malignantupperurinarytractobstructionincancerpatientsasystematicreview AT shobadawson malignantupperurinarytractobstructionincancerpatientsasystematicreview AT jonathananing malignantupperurinarytractobstructionincancerpatientsasystematicreview |